CRESTOR™ (ROSUVASTATIN) REACHES 10 MILLION PRESCRIPTION MILESTONE

CRESTOR is now approved in 64 countries worldwide and is taken by more than three million patients to reduce their LDL-C. People with raised levels of LDL-C are predisposed to cardiovascular disease, which kills over 17 million people worldwide each year.

Arrival at this significant milestone coincides with an update of the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database, following submission of the Periodic Safety Update Report (PSUR) by AstraZeneca. This database continues to show that the safety profile of CRESTOR remains in line with that of other marketed statins.

Studies have shown that CRESTOR lowers LDL-C significantly more than the same and some higher doses of other commonly used statins. Moreover, CRESTOR 10mg gets significantly more patients to their LDL-C goal than the most commonly prescribed doses of other widely used statins – thereby avoiding the need to titrate doses.

Commenting on the milestone, Dr Gunnar Olsson, Head of Cardiovascular, AstraZeneca, said “ It is the goal of all physicians to treat their patients according to defined goals. CRESTOR offers the opportunity to do just that: using the usual start dose of 10mg brings 8 out of 10 patients to their LDL-C goal. With the number of patients on CRESTOR increasing at the rate we’ve seen, it’s clear physicians are recognising these benefits.”

Further enquiries to:

Media Enquiries:

Steve Brown, +44 207 304 5033
Edel McCaffrey, +44 207 304 5034

Investor Enquiries:

Jonathan Hunt, +44 207 304 5087
Mina Blair-Robinson, +44 207 304 5084





Notes to Editors

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

For more information, please visit http://www.astrazeneca.com